{"name":"Atossa Therapeutics","slug":"atossa","ticker":"ATOS","exchange":"NASDAQ","domain":"atossatherapeutics.com","description":"Atossa Therapeutics is a biopharmaceutical company focused on developing innovative therapeutics for oncology and breast cancer prevention. The company's pipeline includes Endoxifen, a proprietary oral formulation of tamoxifen, and MammaPrint, a breast cancer risk assessment tool. Atossa Therapeutics is a relatively small player in the oncology space, but its innovative approach and partnerships with leading institutions position it for growth.","hq":"Seattle, WA","founded":0,"employees":"","ceo":"Steven C. Quay","sector":"Oncology / Breast Cancer Prevention","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$180M","metrics":{"revenue":1758,"revenueGrowth":0,"grossMargin":0,"rdSpend":21185000,"netIncome":-34770000,"cash":47608000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Endoxifen patent cliff ($0.0B at risk)","drug":"Endoxifen","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AT-301A","genericName":"AT-301A","slug":"at-301a","indication":"Other","status":"phase_1"},{"name":"AT-301B","genericName":"AT-301B","slug":"at-301b","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AT-301A","genericName":"AT-301A","slug":"at-301a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AT-301B","genericName":"AT-301B","slug":"at-301b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"earnings","headline":"Atossa Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Atossa Therapeutics reported its financial results for the fourth quarter and full year 2022, with a net loss of $13.4 million and $54.4 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2022-06-28","type":"deal","headline":"Atossa Therapeutics Announces Collaboration with the University of California, San Francisco (UCSF)","summary":"Atossa Therapeutics announced a collaboration with the University of California, San Francisco (UCSF) to study the use of Endoxifen in patients with breast cancer.","drugName":"","sentiment":"positive"},{"date":"2021-12-16","type":"regulatory","headline":"Atossa Therapeutics Receives FDA Clearance for its Endoxifen Clinical Trial","summary":"Atossa Therapeutics received FDA clearance for its clinical trial of Endoxifen in patients with breast cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPZ292SkFsamFJTG1zNHBmUnVpcExBcXMzTHBfcHRCS21iZHo5b0JSSUxlcDhxSU5xQi1vcGpnTDgtczZ5ZlAwRkY3bWF2OWxScllsNlY1RzRSQjRlVjJyZ0czSE4yWnh5bkVhcUs3TG9zLVJXa3JjSmt2UDN5NUhJRTZIbmtvS2NKd2IyYlFITkVHR1UtYjdjcGdobkhNMTVSS0NtajZFTWNkNXFQeEx1enp4U1dUYk82allpUA?oc=5","date":"2026-03-19","type":"trial","source":"Stock Titan","summary":"Atossa hires 2 veteran doctors to steer breast cancer and rare disease trials - Stock Titan","headline":"Atossa hires 2 veteran doctors to steer breast cancer and rare disease trials","sentiment":"neutral"},{"date":"2026-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQMmh2VUd3a0JadTI2MF9tNzhfMnhCRTc3b2dEMGp5YmY4aTVNeTVwRFpjRDFUWTVmQXYwMHgzWGZhaGFSUUxJaGdXOWFueF9kMl90ZXA5dEFMQ3ZJQ3d3Z0MwVi1kY1lNZGQxbzZPNzh1OElWTnFVaC1rWjdwMkhMMkwyUmkzSFpBLS1IaEJDdmRhbGV6d3dZaUJweXMyNGcwc1JCaHNHXy0wMXJRblNHc3lkZjNuZTg1bEU3TTJOamx5eFlITVBiczVFaVcycG1DQ2JRNkVuT205RHM?oc=5","date":"2026-01-27","type":"earnings","source":"simplywall.st","summary":"Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) Profit Outlook - simplywall.st","headline":"Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) Profit Outlook","sentiment":"neutral"},{"date":"2026-01-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPLTdqVDB1QXBRWlRkY1l4X1RPMHJzVm1yMW93WDgyOGNrcWJtMW9fN2tWUVJmMGJuZWxhRzkyMVI1QXYyUXdvdGs1b0xJbFBZcHA4UTBfUzZmTlc5dU5iNVR6TnJxTlo3RFZBV2FsR1RvTmpCcXFDM2pyWWlsV0V5dFBhT3pIaUpFNnZUUjNlWHZuaVlJbFlRV2xPdk9PZFQ5SVJ3R20tNHhjODVZbHFXdF9NbmgtY2ZYSW5LUzUxTmNFSUJFaS1mQ1h1ZHZTRENUakNRTGh4b2YycTE4SnJpQ05GTWVvOF9iZm5hXzNjdWxGeElZc1NpMHN0VEUtSjVRZ25CRjQxN0c?oc=5","date":"2026-01-16","type":"regulatory","source":"PR Newswire","summary":"Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - PR Newswire","headline":"Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystro","sentiment":"neutral"},{"date":"2026-01-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPUmFwUlNVeUdNdHI3UjVMOWtvLVA2b3JuQzJRSzdqSXJsZmZDdUptakE5RE01UERtTm9GM2hKQXhvTkdLNFc0eUo4XzZPWTJhNkFyOFNTRjAtaHNlTWFKam8yeHhQM2ZhSENRWlFlNkhVc2JtcEh4Z091UzhCWkx0WXhIQnY2T0J0T1RTc01mYWlmcFVpbVoxeERpZ1Y3MldUeHlpYVdNVzJvaTg?oc=5","date":"2025-12-11","type":"pipeline","source":"Benzinga","summary":"Why Are Shares Of Atossa Therapeutics Up Today? - Benzinga","headline":"Why Are Shares Of Atossa Therapeutics Up Today?","sentiment":"neutral"},{"date":"2025-12-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-03","type":"pipeline","source":"simplywall.st","summary":"Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth? - simplywall.st","headline":"Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPNl9lU3FfRDB2aUVKbXpBZHNxZjRFbVRjNFppQjJ0WUtkTFg3bFp5QVk4SnR5aGUxU1A2dFh2R1pIY0JEcjViUjlEQUo1aVh4MGxBcV9SZzk4N0xYUnFHdE9TOTBBdmRYM0ZocnE2aVFBbnRqa0J3b3ZSN3piNHNycEhRRkNwZG9MUDJGT0doVFktYXM2ZkR4YkdWamJSNy1obFluQ2V5OC1sSzlZNDFWZlRCTERvdGJCcW5XQWgyV3htZ2duRWdlWmVvRGJaUmZTdDZUZ2FhRjJ6el93ZjE3UnJxdUlselE?oc=5","date":"2025-11-12","type":"earnings","source":"PR Newswire","summary":"Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - PR Newswire","headline":"Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update","sentiment":"neutral"}],"patents":[{"drugName":"Endoxifen","drugSlug":"tamoxifen","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","AstraZeneca","Novartis"],"therapeuticFocus":["Oncology","Breast Cancer Prevention"],"financials":{"source":"sec_edgar","revenue":1758,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":1758,"period":"2015-12-31"},{"value":1758,"period":"2015-12-31"},{"value":525954,"period":"2014-12-31"},{"value":40138,"period":"2014-12-31"},{"value":1115900,"period":"2013-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":21185000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-34770000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":47608000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}